➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Moodys
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Litigation Details for Indivior, Inc. v. Dr. Reddy's Laboratories S.A. (D. Del. 2014)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Indivior, Inc. v. Dr. Reddy's Laboratories S.A. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-12-02
Court District Court, D. Delaware Date Terminated 2019-09-05
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties AQUESTIVE THERAPEUTICS, INC.; DR. REDDY'S LABORATORIES INC.; DR. REDDY'S LABORATORIES SA; INDIVIOR INC.; INDIVIOR UK LIMITED; LTS LOHMANN THERAPY SYSTEMS CORP.
Patents 6,572,497; 6,793,931; 8,017,150; 8,603,514; 9,603,931; 9,931,305; 9,931,334
Attorneys Alexandra Lu; Ashley Kwon; David M. Fry; Elaine H. Blais; Erica N. Anderson; Ira J. Levy; Jack B. Blumenfeld; James F. Hibey; Jamie Lucia; Jeffrey B. Elikan; Jeffrey H. Lerner; Jeremy A. Tigan; John Coy Stull; John W. Shaw; Karen Elizabeth Keller; Kathryn M. Kosinski; Molly R. Grammel; R. Jason Fowler; Rachel M. Hofstatter; Richard D. Kirk; Robert E. Browne , Jr.; Robert Frederickson , III.; Sara E. Bussiere; Stephen B. Brauerman; Timothy C. Bickham
Firms Bayard, P.A.; Morris, Nichols, Arsht & Tunnell; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Indivior, Inc. v. Dr. Reddy's Laboratories S.A.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Indivior, Inc. v. Dr. Reddy's Laboratories S.A.
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Indivior, Inc. v. Dr. Reddy's Laboratories S.A. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2020-04-23 361 Opinion - Memorandum Opinion 8,603,514 (“the ’514 patent”), 8,017,150 (“the ’150 patent”), and 8,900,497 (“the ’497 patent”). (Id.). The …ʼ497, and ʼ150 patents, the case was not “exceptionally meritless.” Octane Fitness, 572 U.S. at 555. While… #: 16256 elastic film” limitation of the ’497 patent was frivolous because Plaintiffs did not proffer… certain of DRL’s formulations infringed the ’497 patent” and that no testing was done to see if DRL’…finding that Defendants did not infringe the ‘497 patent (see D.I. 335 at 16-17), but only poor lawyers External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
Medtronic
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.